Nektar Therapeutics slumps after pain drug fails

by admin on September 28, 2013

Shares of Nektar Therapeutics plunged Friday after the company said its pain drug NKTR-181 failed in a clinical trial. THE SPARK: Nektar was studying NKTR-181 as a treatment for moderate to severe pain …

View full post on pain – Yahoo News Search Results

Previous post:

Next post: